| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | osimertinib (Tagrisso®) |
| Formulation | 40 mg & 80 mg film-coated tablet |
| Reference number | 2591 |
| Indication | The first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations |
| Company | AstraZeneca UK Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 26/07/2018 |
| NICE guidance | TA654: Osimertinib for untreated EGFR mutation-positive non-small-cell lung cancer |
| Commercial arrangement | PAS |